Dunkirk, N.Y.
Athenex is constructing a $210 million pharmaceutical plant in Dunkirk, N.Y. Supporting the production of advanced cancer therapies, the 409,000-sf complex will provide research, office, manufacturing, and warehouse space. General contractor Exyte broke ground on the facility in May of 2018, and commercial operations will commence at the site in early 2022. The project is part of a strategic infrastructure development plan to enable Athenex to offer vertically integrated oncology services from discovery through marketing. The company, which is based in Buffalo, N.Y., has recently completed a 440,000-sf facility in Chongqing, China.
| Organization | Project Role |
|---|---|
|
Exyte
|
General Contractor
|
